全文获取类型
收费全文 | 48529篇 |
免费 | 3739篇 |
国内免费 | 157篇 |
专业分类
耳鼻咽喉 | 520篇 |
儿科学 | 1455篇 |
妇产科学 | 1044篇 |
基础医学 | 6185篇 |
口腔科学 | 1444篇 |
临床医学 | 4979篇 |
内科学 | 10253篇 |
皮肤病学 | 1093篇 |
神经病学 | 4465篇 |
特种医学 | 1133篇 |
外国民族医学 | 1篇 |
外科学 | 7158篇 |
综合类 | 723篇 |
一般理论 | 27篇 |
预防医学 | 4971篇 |
眼科学 | 858篇 |
药学 | 3274篇 |
中国医学 | 141篇 |
肿瘤学 | 2701篇 |
出版年
2023年 | 351篇 |
2022年 | 256篇 |
2021年 | 1418篇 |
2020年 | 872篇 |
2019年 | 1447篇 |
2018年 | 1723篇 |
2017年 | 1114篇 |
2016年 | 1065篇 |
2015年 | 1335篇 |
2014年 | 1867篇 |
2013年 | 2439篇 |
2012年 | 3622篇 |
2011年 | 3824篇 |
2010年 | 2053篇 |
2009年 | 1865篇 |
2008年 | 2933篇 |
2007年 | 3022篇 |
2006年 | 2868篇 |
2005年 | 2721篇 |
2004年 | 2423篇 |
2003年 | 2200篇 |
2002年 | 2128篇 |
2001年 | 747篇 |
2000年 | 669篇 |
1999年 | 572篇 |
1998年 | 342篇 |
1997年 | 288篇 |
1996年 | 296篇 |
1995年 | 246篇 |
1994年 | 236篇 |
1993年 | 217篇 |
1992年 | 403篇 |
1991年 | 399篇 |
1990年 | 409篇 |
1989年 | 350篇 |
1988年 | 282篇 |
1987年 | 297篇 |
1986年 | 246篇 |
1985年 | 274篇 |
1984年 | 235篇 |
1983年 | 178篇 |
1982年 | 167篇 |
1981年 | 146篇 |
1980年 | 133篇 |
1979年 | 186篇 |
1978年 | 155篇 |
1977年 | 108篇 |
1976年 | 111篇 |
1974年 | 143篇 |
1973年 | 117篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Francisco Javier P rez Lara Maria Belen Jimenez Martinez Francisco Pozo Mu oz res Fontalba Navas Rogelio Garcia Cisneros Maria Jose Garcia Larrosa Ignacio Garcia Delgado Maria del Mar Callejon Gil 《World Journal of Clinical Cases》2021,9(23):6582-6590
The coronavirus disease 2019, which is caused by severe acute respiratory syndrome coronavirus 2, was first identified in December 2019 in Wuhan, China, and has since spread rapidly, evolving into a full-blown pandemic. We would like to report our experience after 1 year of this pandemic in the surgical service of a district hospital in Spain. There have been many changes (including new protocols) that our service and the hospital have undergone, to adapt to the new situation. We believe that this experience can be useful for other professionals who have lived and are living a similar situation. 相似文献
4.
5.
6.
Mariángeles González Fernández Elena Villamañán Inmaculada Jiménez-Nácher Francisco Moreno Chamaida Plasencia Francisco Gayá Alicia Herrero Alejandro Balsa 《Reumatología clinica》2021,17(6):335-342
ObjectiveTo assess the evolution of cost per patient/year and the cost per patient/year/drug in patients with rheumatoid arthritis (RA) receiving biological treatments. To analyze and quantify the factors influencing this evolution, such as the optimization of the biological drugs, the use of biosimilars, and official discounts and discounts obtained after negotiated procedures. In addition, to assess specific clinical parameters of disease activity in these patients.MethodsRetrospective, observational study conducted in a Spanish tertiary hospital. Adult patients diagnosed with RA under treatment from 2009 to 2017 were included.Results320, 270 and 389 patients were included in 2009, 2013 and 2017, respectively. The patient/year cost decreased from 10,789€ in 2009, 7491€ in 2013 to 7116€ in 2017. In 2017, due to the established competition, discounts of 14% and 29.5% were achieved on etanercept and its biosimilar; 11.5%, 17.8%, 17.9%, 17.3% on adalimumab, certolizumab, golimumab and tocilizumab IV respectively, and 24.6% and 43.1% on infliximab and its biosimilar. The percentage of patients optimized in 2017 was 35.2%. The annual saving in 2017 was 1,288,535€ (830,000€ due to dose optimization and/or administration regimens, 249,666€ corresponding to 7.5% of the official discount and 208,868€ after negotiated procedures).ConclusionThe annual cost per patient in RA decreased considerably due to different factors, such as discounts on the purchase of drugs due to official discounts and negotiated procedures, together with the optimization of therapies, the latter being the factor that contributed most to this decrease. 相似文献
7.
8.
Neal Bhutiani Elizabeth H. Bruenderman Jordan M. Jones John H. Wehry Michael E. Egger Prejesh Philips Charles R. Scoggins Kelly M. McMasters Robert C.G. Martin 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2021,23(1):63-70
BackgroundThe optimal timing of treatment of liver metastases from low-grade neuroendocrine tumors (LG-NELM) varies significantly due to numerous treatment modalities and the literature supporting various treatment(s). This study sought to create and validate a literature-based treatment algorithm for LG-NELM.MethodsA treatment algorithm to maximize overall survival (OS) was designed using peer-reviewed articles evaluating treatment of LG-NELM. This algorithm was retrospectively applied to patients treated for LG-NELM at our institution. Deviation was determined based on whether or not a patient received treatment consistent with that recommended by the algorithm. Patients who did and did not deviate from the algorithm were compared with respect to OS and number of treatments.ResultsApplying our algorithm to a 149-patient cohort, 57 (38%) deviated from recommended treatment. Deviation occurred in the form of alternative (28, 49%) versus additional procedures (29, 51%). Algorithm deviators underwent significantly more procedures than non-deviators (median 1 vs. 2, p < 0.001). Cox model indicated no difference in OS associated with algorithm deviation (HR 1.19, p = 0.58) when controlling for age and tumor characteristics.ConclusionThis literature-based algorithm helps standardize treatment protocols in patients with LG-NELM and can reduce cost and risk by minimizing unnecessary procedures. Prospective implementation and validation is required. 相似文献
9.
10.
Many patients with terminal cancer wish to die at home and general practitioners in the United Kingdom have a critical role in providing this care. However, it has been suggested general practitioners lack confidence in end-of-life care. It is important to explore with general practitioners their experience and perspectives including feelings of confidence delivering end-of-life care to people with cancer. The aim of this study was to explore general practitioners experiences of providing end-of-life care for people with cancer in the home setting and their perceptions of confidence in this role as well as understanding implications this has on policy design. A qualitative study design was employed using semi-structured interviews and analysed using thematic analysis. Nineteen general practitioners from London were purposively sampled from eight general practices and a primary care university department in 2018–2019, supplemented with snowballing methods. Five main themes were constructed: (a) the subjective nature of defining palliative and end-of-life care; (b) importance of communication and managing expectations; (c) complexity in prescribing; (d) challenging nature of delivering end-of-life care; (e) the unclear role of primary care in palliative care. General practitioners viewed end-of-life care as challenging; specific difficulties surrounded communication and prescribing. These challenges coupled with a poorly defined role created a spread in perceived confidence. Experience and exposure were seen as enabling confidence. Specialist palliative care service expansion had important implications on deskilling of essential competencies and reducing confidence levels in general practitioners. This feeds into a complex cycle of causation, leading to further delegation of care. 相似文献